Technology
Brain Shuttles for the Next Generation of CNS Therapeutics
Our Brain Shuttles are based on deimmunised single domain VNAR antibodies originating from the shark. VNAR scaffold architecture allows binding to unreachable by conventional antibody epitopes, thus delivering unique biological effects. Preference for conformational epitopes increases target specificity; which allows plasticity in binding and dissociation upon structural changes to the target receptor undergoing transcytosis across the Blood-Brain Barrier.
Ready for Clinical Application
TXP1
Brain Shuttle
Based on the Deimmunised VNAR Antibody Scaffold and Targeting TfR1 for Efficient Receptor Mediated Transcytosis Across the Blood-Brain Barrier
High Brain Delivery
Improves delivery of therapeutics across the BBB to the brain parenchyma in primates by >30-fold
Optimal Binding
Optimised receptor binding kinetics for efficient transcytosis across the BBB
Deimmunised
Based on the deimmunised VNAR antibody scaffold
Lasting
Prolonged brain exposure and slow blood clearance at low doses
For Mouse Models
Optimal Mouse Brain Shuttle
Surrogate Brain Shuttle Ideal for Mouse Models and Easy Progression Through Efficacy Proof-of-Concept Stage
Opportunities Beyond the Blood-Brain Barrier
Pipeline
Delivery of Therapeutics Across the Blood-Brain Barrier Presents New Opportunities for the Next Generation CNS Therapies
Publications
Proven Peer-Reviewed Technology
Blood-brain barrier transport using a high affinity, brain-selective VNAR antibody targeting TfR1
Stocki P et al. 2021
Brain delivery of biologics using a cross-species reactive transferrin receptor 1 VNAR shuttle
Sehlin D et al. 2020
A Single Domain Shark Antibody Targeting TfR1 Delivers a TrkB Agonist Antibody to the Brain and Provides Full Neuroprotection in a Mouse Model of Parkinson's Disease
Clarke E et al. 2022
CDR3 Variants of the TXB2 Shuttle with Increased TfR1 Association Rate and Enhanced Brain Penetration
Stocki P et al. 2023